EMP1 and non-small cell lung carcinoma: In addition, EMP1 mRNA expression is correlated with the acquisition of gefitinib resistance in patients with NSCLC, and the correlation is independent of gefitinib-sensitizing mutations in epidermal growth factor receptor [68].